Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter – – Long-term follow-up data from ...

Evercore ISI analyst Cory Kasimov initiated coverage of SpringWorks Therapeutics (SWTX) with an Outperform rating and $60 price target ...

StockNews.com started coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Free Report) in a research note issued to investors on Monday. The brokerage set a “sell” rating on the stock.

TD Cowen analyst Tyler Van Buren has reiterated their bullish stance on IMNM stock, giving a Buy rating on November 7. Tyler Van Buren has ...

Brooke began taking OGSIVEO on December 30, 2023, just a month after it was approved by the FDA for adults with progressing ...

Achieved $49.3 million in OGSIVEO® (nirogacestat) net product revenue in the third quarter - - Long-term follow-up data from the Phase 3 DeFi trial of nirogacestat in adults with desmoid tumors highli ...

Encouraging results from Phase 1/2 study of mirdametinib in pediatric patients with low-grade glioma also to be presented in oral session at SNO – STAMFORD, Conn., (GLOBE NEWSWIRE) -- SpringWorks ...

SpringWorks to present long-term efficacy and safety data from phase 3 DeFi trial of Ogsiveo in adults with desmoid tumours at CTOS 2024 meeting ...

Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...